

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims**

1. – 14. (Canceled)

15. (Currently amended) A method for increasing the level of expression of transferred genetic material into a mammalian cell, the method comprising the steps, of

(a) preparing a transfected mammalian cell by transferring into said cell,

(i) a first polynucleotide comprising a promotor operably linked to the coding sequence of p21; and

(ii) a second polynucleotide comprising a promotor operably linked to a coding sequence; and

(b) maintaining said transfected mammalian cell under conditions conducive to synthesizing p21, wherein the stable transfer of genetic material results in enhanced expression levels of the second polynucleotide.

16. (Previously presented) The method of claim 15, wherein the first and/or second polynucleotide comprises a viral vector.

17. (Previously presented) The method of claim 16, wherein the viral vector is selected from the group consisting of retroviral vectors, adenoviral vectors, baculoviral vectors, parvoviral vectors and herpes viral vectors.

18. (Previously presented) The method of claim 15, wherein the viral vector is an adenoviral vector.

19. (Previously presented) The method of claim 15, wherein increased level of expression the mammalian cell is transfected *in vitro*.
20. (Previously presented) The method of claim 15, wherein the mammalian cell is an established cell line or a primary culture.
21. (Previously presented) The method of claim 15 wherein the mammalian cell is transfected *in vivo*.
22. (Previously presented) The method of claim 21 wherein the mammalian cell is a rodent cell.
23. (Previously presented) The method of claim 21 wherein the mammalian cell is a human cell.
24. (Currently amended) The method of claim 15, wherein the mammalian cell is ~~tumorigenic or non-tumorigenic~~ tumorigenic cell.
25. (Previously presented) The method of claim 15, wherein the improved stability results from p21-mediated inhibition of apoptosis.
26. (Previously presented) The method of claim 15 wherein the improved stability results from the p21-mediated inhibition of cytotoxicity.